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Letters to the Editor 367improved subsequently with full recovery. Amphotericin
and flucytosine were stopped after two weeks and were
followed by oral fluconazole for six months. He was HIV
negative. Lymphocyte subsets count and lymphocyte pro-
liferation assay were normal. He had no relapse for five
years.
Cryptococcosis is an important diagnosis for immuno-
compromised subjects,1,2 and is increasingly recognized in
the immunocompetent host.3,4 Meningitis is common in
cryptococcosis.2,5—8 Our patient had cryptococcal meningi-
tis presenting with neck pain and headache with raised ICP.
The raised ICP aggravated his hypertension via the Cushing
reflex. During the Cushing reflex, the systemic arterial
blood pressure rises in response to central nervous system
(CNS) ischemia caused by an ICP that is equal or higher than
the arterial pressure. Without end-organ damage, we
believed that his papilloedema was due to raised ICP
instead of malignant hypertension. CNS infection was not
considered initially due to the lack of fever and the pre-
sumptive diagnosis of headache due to uncontrolled hyper-
tension. The clue for CNS infection on initial presentation
was the neck pain. He deteriorated later with encephalo-
pathy, nuchal rigidity, and severe intracranial hypertension
causing papilloedema and sixth nerves compression. Upon
incidental normalization of his BP, his level of consciousness
deteriorated, which improved as his BP surged up, reflect-
ing that when cerebral autoregulation is impaired due to
meningitis, a high systemic BP is required to maintain
adequate cerebral blood flow during intracranial hyperten-
sion. This was documented objectively by the transcranial
Doppler findings.
Raised ICP causing reactive hypertension without fever or
signs of meningism can be the presenting feature of crypto-
coccal meningitis in an immunocompetent host. Clinicians
should consider CNS infection causing raised ICP when hyper-
tension and papilloedema are present without evidence of
end-organ damage to suggest malignant hypertension.
Prompt initiation of anti-fungal therapies is critical for this
potentially fatal meningitis.
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doi:10.1016/j.ijid.2006.07.005The use of ELISA in a seroprevalence study of
Brucella antibodies in West Bank Palestinian
women of childbearing age
Brucellosis is considered to be endemic in the Mediterra-
nean basin and the Middle East;1,2 Brucella melitensis is
the only Brucella species currently known to cause disease
in Israel and the Palestinian Authority.3 While human
incidence statistics from Israel and the Palestinian Author-
ity support endemicity,4,5 this has not previously been
verified by seroprevalence studies. We report a prevalence
study of Brucella antibodies in a West Bank Palestinian
population.
Cord blood was taken at delivery, after informed consent,
from 2638 Palestinian women who gave birth between 31
August 1994 and 31 March 1995 in six West Bank governmenthospitals. Of 1021 samples selected by systemic sampling,
802 were adequate for processing. All were tested by ELISA
for IgG-class Brucella antibodies (Clark). Every sixth sample,
and all ELISA-positive samples with sufficient serum (32/35
positive samples), were tested by Rose-Bengal (Sanofi) and
agglutination (SAT; Murex) tests.
Of the samples, 35/802 (4.4%) were positive by ELISA.
Nine of 32 (28.1%) ELISA-positive samples had SAT titers
1:50; one (1:400 titer) was positive by Rose-Bengal test.
All ELISA-negative samples were SAT-negative. ELISA preva-
lence varied from 3% in the summer to 7—10% in early spring
(Figure 1). Neither this nor variation by age (from 2.5% for
ages 20—24 years to 7% in the>30 years age group) or hospital
(1.3—6%) was statistically significant.
ELISA detects Brucella IgG antibodies reflecting both past
seroconversion and current disease.2,6,7 ELISA tests combine
high specificity and sensitivity and a relatively low unit
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Figure 1 Percentage of samples positive by ELISA for Brucella
for each month of the study. The overall percentage of ELISA-
positive samples in the study population was 4.4%.cost;8,9 in clinical practice, ELISA could be useful in screening
suspected brucellosis cases among low-incidence populations
and as a supplementary assay in endemic areas in cases of
high clinical suspicion.
In the study population, no information was obtained as to
the presence or absence of brucellosis risk factors or symp-
toms. The Rose-Bengal test-positive sample, with a 1:400 SAT
titer, was probably a case of acute or recent brucellosis. For
those women with titers 50—200 and a negative Rose-Bengal
test, clinical correlation would determine which had active
or recent disease, or asymptomatic exposure.
The Brucella antibody prevalence of 4.4% provides strong
evidence for the endemicity of brucellosis, and is similar to
that reported in neighboring regional countries.1,10 Since this
study, a Brucella control program was instigated, which
initially led to a decreased incidence in Israel, followed in
recent years by a renewed increase.3,4 This, combined with
our evidence of endemicity in a West Bank female popula-
tion, re-emphasizes the need for regional brucellosis control
programs. A high index of suspicion for brucellosis is in order
in the presence of appropriate risk factors.
The data included in this manuscript were presented as a
poster at the Israeli Society of Infectious Diseases annual
meeting, Mitzpe Ramon, Israel, June 2004.
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doi:10.1016/j.ijid.2006.08.002Tuberculosis of major salivary glands: report of
a 7-year experience in Tehran, Iran
Tuberculosis (TB) of major salivary glands (MSG) is a rare
clinical entity with less than 50 cases of parotid and about
five cases of submandibular gland involvement reported sofar.1—10 Herein, we report the prevalence of MSG tuberculosis
in our 7-year experience of MSG masses.
Between 1996 and 2003, a total of 164 patients (83 male,
81 female) were admitted to Imam Khomeini and Amiralam
hospitals, two referral centers in Tehran, Iran, with a diag-
nosis of MSG mass. The mean age of patients was 40.9 (range
4—85) years. Pleomorphic adenoma (the most common diag-
